As the GLP1 therapy landscape shifts in 2026, clinical success is being redefined by more than just numbers on a scale. Join Dr. Sean Wharton for an essential update on the diversification of the GLP-1 market, including the impact of new therapeutic entries on patient access. This session moves beyond weight-centric management to explore the systemic, multi-organ benefits of GLP-1s, providing a blueprint for achieving total metabolic health and long-term quality of life in your patients.
Objectives
Advance the Science of Obesity Management Evaluate the latest clinical data on incretin therapies and the biological mechanisms that drive weight regain and obesity.
Navigate the Expanding Therapeutic Landscape Analyze the clinical role of new and emerging agents, including the impact of increased market options on patient access and treatment selection.
Redefine Clinical Goals in Obesity Medicine Discuss the shift from weight-centric metrics toward holistic outcomes, focusing on metabolic health and long-term quality of life.
Login to Access Registration
Webinar registration is open for existing members. Login to access registration or create your free membership here.